Suven Pharmaceuticals Limited

NSEI:SUVENPHAR Stock Report

Market Cap: ₹324.4b

Suven Pharmaceuticals Valuation

Is SUVENPHAR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SUVENPHAR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SUVENPHAR (₹1274.45) is trading above our estimate of fair value (₹61.94)

Significantly Below Fair Value: SUVENPHAR is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SUVENPHAR?

Key metric: As SUVENPHAR is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for SUVENPHAR. This is calculated by dividing SUVENPHAR's market cap by their current earnings.
What is SUVENPHAR's PE Ratio?
PE Ratio133.4x
Earnings₹2.43b
Market Cap₹324.43b

Price to Earnings Ratio vs Peers

How does SUVENPHAR's PE Ratio compare to its peers?

The above table shows the PE ratio for SUVENPHAR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average85.4x
PFIZER Pfizer
38x12.9%₹234.7b
LAURUSLABS Laurus Labs
201.2x55.6%₹263.7b
EMCURE Emcure Pharmaceuticals
42.8x25.3%₹242.7b
500660 GlaxoSmithKline Pharmaceuticals
59.5x16.8%₹401.7b
SUVENPHAR Suven Pharmaceuticals
133.4xn/a₹324.4b

Price-To-Earnings vs Peers: SUVENPHAR is expensive based on its Price-To-Earnings Ratio (133.4x) compared to the peer average (85.4x).

Price to Earnings Ratio vs Industry

How does SUVENPHAR's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
INDSWFTLAB Ind-Swift Laboratories
1.6xn/aUS$71.82m
524652 Ind-Swift
2xn/aUS$13.29m
No more companies available in this PE range
SUVENPHAR 133.4xIndustry Avg. 32.2xNo. of Companies19PE020406080100+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: SUVENPHAR is expensive based on its Price-To-Earnings Ratio (133.4x) compared to the Indian Pharmaceuticals industry average (32.2x).

Price to Earnings Ratio vs Fair Ratio

What is SUVENPHAR's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SUVENPHAR PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio133.4x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate SUVENPHAR's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SUVENPHAR forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₹1,274.45
₹950.50
-25.4%
39.9%₹1,330.00₹571.00n/a2
Nov ’25₹1,327.15
₹810.50
-38.9%
29.5%₹1,050.00₹571.00n/a2
Oct ’25₹1,202.65
₹810.50
-32.6%
29.5%₹1,050.00₹571.00n/a2
Sep ’25₹1,073.55
₹810.50
-24.5%
29.5%₹1,050.00₹571.00n/a2
Aug ’25₹990.30
₹670.50
-32.3%
14.8%₹770.00₹571.00n/a2
Jul ’25₹824.10
₹670.50
-18.6%
14.8%₹770.00₹571.00n/a2
Jun ’25₹617.30
₹685.50
+11.0%
16.7%₹800.00₹571.00n/a2
May ’25₹660.45
₹685.50
+3.8%
16.7%₹800.00₹571.00n/a2
Apr ’25₹669.70
₹685.50
+2.4%
16.7%₹800.00₹571.00n/a2
Mar ’25₹686.10
₹685.50
-0.09%
16.7%₹800.00₹571.00n/a2
Jun ’24₹474.20
₹613.50
+29.4%
1.4%₹622.00₹605.00₹617.302
May ’24₹471.90
₹613.50
+30.0%
1.4%₹622.00₹605.00₹660.452
Apr ’24₹472.40
₹613.50
+29.9%
1.4%₹622.00₹605.00₹669.702
Mar ’24₹477.10
₹585.67
+22.8%
6.8%₹622.00₹530.00₹686.103
Feb ’24₹492.10
₹589.25
+19.7%
6.0%₹622.00₹530.00₹659.954
Jan ’24₹494.90
₹589.25
+19.1%
6.0%₹622.00₹530.00₹720.354
Dec ’23₹463.95
₹589.25
+27.0%
6.0%₹622.00₹530.00₹674.354
Nov ’23₹407.50
₹590.80
+45.0%
9.9%₹665.00₹530.00₹573.155

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

Bal Pharma

₹2.2b

Manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally.

BALPHARMA

₹134.50

7D

11.6%

1Y

27.4%

Mercury Laboratories

₹1.1b

Develops, manufactures, markets, distributes, and sells pharmaceutical drugs, medicines, and formulations for mother and child healthcare in India and internationally.

538964

₹911.45

7D

-3.5%

1Y

18.7%

Caplin Point Laboratories

₹147.7b

Engages in the development, production, marketing, and export of generic pharmaceutical formulations and branded products in India.

CAPLIPOINT

₹1,942.80

7D

-0.4%

1Y

58.1%